Indacaterol/glycopyrronium bromide

Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:

• Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA);^[2]
• Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.

IndacaterolUltra-long-acting beta-adrenoceptor agonist

Glycopyrronium bromideMuscarinic anticholinergic

Trade namesUltibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler

Pregnancy
category

• AU: B3

Quick facts Combination of, Glycopyrronium bromide ...

Indacaterol/glycopyrronium bromide

Combination of
Indacaterol	Ultra-long-acting beta-adrenoceptor agonist
Glycopyrronium bromide	Muscarinic anticholinergic
Clinical data
Trade names	Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler
Pregnancy category	AU: B3
Routes of administration	Inhalation only
ATC code	R03AL04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only[1] UK: POM (Prescription only) US: ℞-only EU: Rx-only
Identifiers
CAS Number	444313-53-5 Y
PubChem CID	11564052
KEGG	D10505
CompTox Dashboard (EPA)	DTXSID60155126

Close

Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).^[3]

The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.^[3][4] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.^[5]